The Tardive Dyskinesia Therapeutics Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Tardive Dyskinesia Therapeutics Market?
The market size of tardive dyskinesia therapeutics has experienced significant growth recently. In 2024, the market was valued at $2.9 billion and is projected to increase to $3.12 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.5%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Tardive Dyskinesia Therapeutics Industry?
The Tardive Dyskinesia Therapeutics Global Market is expected to reach $4.11 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.2%.
Download Your Free Sample of the 2025 Tardive Dyskinesia Therapeutics Market Report and Uncover Key Trends Now!
Global Market Segmentation: Identifying Major Tardive Dyskinesia Therapeutics Industry Segments
The tardive dyskinesia therapeutics market covered in this report is segmented –
1) By Drug: Deutetrabenazine, Valbenazine, Other Drugs
2) By Product Type: Solid Dosage Forms, Tablets, Capsules, Liquid Dosage Form, Injection
3) By Application: Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, Idiopathic Tardive Dyskinesia
4) By End-User: Hospitals, Clinics, Specialty Treatment Centers, Homecare Settings
What are the Key Growth Drivers Fueling the Tardive Dyskinesia Therapeutics Market?
The key drivers in the tardive dyskinesia therapeutics marketare:
• Rising mental health disorder burden
• Expanding research and development activities in the field
• Increased investment by pharmaceutical companies
• Growing preference for personalized medicine and improved healthcare infrastructure.
Pre-order the 2025 Tardive Dyskinesia Therapeutics Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Tardive Dyskinesia Therapeutics Market?
The key trends in the tardive dyskinesia therapeutics market are:
• Strategic collaborations between pharmaceutical companies and research institutes for novel therapies is an eminent trend.
• Development and usage of extended-release formulations is a rising trend in the market.
• The emergence of generic versions of drugs is a significant upcoming trend.
• The market is being shaped by regulatory incentives such as orphan drug designations and advancements in drug delivery technologies.
Who Are the Top Competitors & Leading Players in the Tardive Dyskinesia Therapeutics Market?
Major companies in the tardive dyskinesia therapeutics market are:
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Lundbeck A/S
• Amneal Pharmaceuticals Inc.
• Lupin Pharmaceuticals Inc.
• Neurocrine Biosciences Inc.
• Luye Pharma Ltd.
• Lannett Co. Inc.
• SteriMax Inc.
• Zydus Cadila Healthcare Ltd.
• Adamas Pharmaceuticals Inc.
• Mitsubishi Tanabe Pharma Corporation
• SOM Biotech Ltd.
• Addex Therapeutics
Regional Dominance: Which Area Leads the Global Tardive Dyskinesia Therapeutics Market?
North America was the largest region in the tardive dyskinesia therapeutics market in 2024
